Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer

Gastric Cancer

Volumn 14, Issue 2, 2011, Pages 155-160

  Shitara, Kohei ^a   Matsuo, Keitaro ^a   Mizota, Ayako ^a   Kondo, Chihiro ^a   Nomura, Motoo ^a   Takahari, Daisuke ^a   Yokota, Tomoya ^a   Ura, Takashi ^a   Ito, Seiji ^a   Sawaki, Akira ^a   Tajika, Masahiro ^a   Kawai, Hiroki ^a   Muro, Kei ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Fluorouracil; Gastric cancer; Irinotecan; Paclitaxel; Platinum agent

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROPYRIMIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH CANCER; SURVIVAL TIME; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COHORT STUDIES; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TAXOIDS;

EID: 79959374724     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0019-3     Document Type: Article

References (19)

1. International Agency for Research on Cancer GLOBOCAN 2008. http://www-dep.iarc.fr/CancerMondial.htm.
2. E Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni, et al. 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991 4997 17075117 10.1200/JCO.2006.06.8429 (Pubitemid 46631401)
3. D Cunningham N Starling S Rao T Iveson M Nicolson F Coxon, et al. 2008 Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36 46 18172173 10.1056/NEJMoa073149 1:CAS:528:DC%2BD1cXisFSktg%3D%3D
4. W Koizumi H Narahara T Hara A Takagane T Akiya M Takagi, et al. 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 221 18282805 10.1016/S1470-2045(08)70035-4 1:CAS:528:DC%2BD1cXivVaqtb4%3D
5. YK Kang WK Kang DB Shin J Chen J Xiong J Wang, et al. 2009 Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 666 673 19153121 10.1093/annonc/mdn717
6. JA Ajani W Rodriguez G Bodoky V Moiseyenko M Lichinitser V Gorbunova, et al. 2010 Multicenter phase III comparison of cisplatin/s-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial J Clin Oncol 28 1547 1553 20159816 10.1200/JCO.2009.25.4706 1:CAS:528:DC%2BC3cXltFGhtr0%3D
7. NCCN Clinical Practice Guidelines in Oncology (2010) Gastric Cancer. NCCN practice guidelines in oncology, version 2.
8. H Takiuchi H Fukuda N Boku Y Shimada J Nasu Y Hamamoto, et al. 2010 Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407) J Clin Oncol 28 18s (suppl; LBA4513)
9. A Takashima N Boku K Kato J Mizusawa K Nakamura H Fukuda, et al. 2010 Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC): results from combined analysis of JCOG9205 and JCOG9912 J Clin Oncol 28 15s (suppl; abstr 4061)
10. N Boku S Yamamoto H Fukuda K Shirao T Doi A Sawaki, et al. 2009 Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 1063 1069 19818685 10.1016/S1470-2045(09)70259-1 1:CAS:528:DC%2BD1MXhtlGit7bI
11. K Chin H Iishi H Imamura O Kobayashi H Imamoto T Esaki, et al. 2007 Irinotecan plus S-1 (IRIS) versus S-1 alone as first line treatment for advanced gastric cancer: preliminary results of a randomized phase III study (GC0301/TOP-002) J Clin Oncol 25 18 s (suppl; abstr 4525)
12. M Dank J Zaluski C Barone V Valvere S Yalcin C Peschel, et al. 2008 Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Ann Oncol 19 1450 1457 18558665 10.1093/annonc/mdn166 1:STN:280: DC%2BD1cvotFCmtA%3D%3D
13. PC Thuss-Patience A Kretzschmar T Deist A Hinke D Bichev B Lebedinzew, et al. 2009 Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) J Clin Oncol 27 15 s (suppl; abstr 4540)
14. A Ohtsu Y Shimada K Shirao N Boku I Hyodo H Saito, et al. 2003 Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205) J Clin Oncol 21 54 59 12506170 10.1200/JCO.2003.04.130 1:CAS:528:DC%2BD2cXpsVWru7k%3D
15. K Shirao N Boku Y Yamada K Yamaguchi T Doi H Takiuchi, et al. 2009 Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106) J Clin Oncol 27 15 s (suppl; abstr 4545)
16. AD Wagner W Grothe J Haerting G Kleber A Grothey WE Fleig 2006 Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2903 2909 16782930 10.1200/JCO.2005.05. 0245 1:CAS:528:DC%2BD28XntV2gs7s%3D (Pubitemid 46630593)
17. A Grothey D Sargent RM Goldberg HJ Schmoll 2004 Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 22 1209 1214 15051767 10.1200/JCO.2004.11.037 1:CAS:528: DC%2BD2cXpsVGktLo%3D (Pubitemid 41079833)
18. D Kelsen M Jhawer D Ilson A Tse J Randazzo E Robinson, et al. 2009 Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: results of a phase II clinical trial (2009) J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695 (suppl; abstr 4512)
19. MA Hernán B Brumback JM Robins 2001 Marginal structural models to estimate the joint effect of non-randomized treatments J Am Stat Assoc 96 440 448 10.1198/016214501753168154 (Pubitemid 33283729)